Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as NMDA Antagonist, CP-101,606 (traxoprodil)
NMDA Antagonist, CP-101, 606 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| NMDA Antagonist, CP-101,606 (traxoprodil) | DRUG | - |
Inclusion Criteria: * Primary DSM-IV diagnosis of MDD Exclusion Criteria: * Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, bu...
NMDA Antagonist, CP-101,606 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE) for major depressive disorder. It is also known as traxoprodil. It has been studied in a Phase 2 clinical trial and is not an approved treatment.
NMDA Antagonist, CP-101,606 was studied for the treatment of major depressive disorder, a condition in the psychiatry therapeutic area. The clinical research evaluated its antidepressant effects in adult patients with MDD. It is an investigational agent and has not been approved for any use.
Pfizer, Inc., which trades under the ticker PFE, is the developer of NMDA Antagonist, CP-101,606. Pfizer sponsored the clinical research program for this compound in major depressive disorder.
NMDA Antagonist, CP-101,606 is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The compound remains investigational and has not received FDA approval for major depressive disorder or any other indication.
NMDA Antagonist, CP-101,606 was evaluated in a single completed Phase 2 study, NCT00163059, titled The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD. The trial enrolled 30 adults with major depressive disorder in the United States and used a randomized, uncontrolled design.
Yes, NMDA Antagonist, CP-101,606 is also known as traxoprodil. Both names refer to the same Pfizer small molecule compound studied in Phase 2 for major depressive disorder. Searches for either name point to the same investigational asset.